Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

TCT 2021 | Real-world treatment patterns & outcomes of functional high-risk myeloma

Ankit Kansagra • 8 Feb 2021
TCT 2021
Multiple Myeloma

Ankit Kansagra, MD, UT Southwestern Medical Center, Dallas, TX, outlines the real-world treatment patterns and outcomes of patients with functional high-risk multiple myeloma. In this retrospective study, Dr Kansagra indicates that half of functional high-risk patients recieved stem cell transplantation in second line. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Ankit Kansagra

An analysis on patients with high-risk multiple myeloma 4:06
An analysis on patients with high-risk multiple myeloma
Ankit Kansagra • 16 Dec 2021
Autologous stem cell transplant for POEMS Syndrome 2:56
Autologous stem cell transplant for POEMS Syndrome
Ankit Kansagra • 16 Dec 2021
Future of myeloma treatment 2:18
Future of myeloma treatment
Ankit Kansagra • 8 Feb 2021
KarMMa: characterizing incidence of CRS in R/R myeloma 3:53
KarMMa: characterizing incidence of CRS in R/R myeloma
Ankit Kansagra • 8 Feb 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals